Page last updated: 2024-11-03

promethazine and Parkinsonian Disorders

promethazine has been researched along with Parkinsonian Disorders in 6 studies

Promethazine: A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals.
promethazine : A tertiary amine that is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropan-2-amine moiety.

Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.

Research Excerpts

ExcerptRelevanceReference
"Promethazine (PMZ) is an FDA-approved antihistaminergic drug that was identified as a potentially neuroprotective compound in the NINDS screening program."1.33Promethazine protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. ( Beal, MF; Calingasan, NY; Chen, J; Cleren, C; Lorenzo, BJ; Starkov, AA, 2005)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19905 (83.33)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
TOLAN, EJ1
OLARIU, J1
GERSTENBRAND, F1
PATEISKY, K1
STJEAN, A1
DONALD, M1
BAN, TA1
BOVET, D1
DUREL, P1
LONGO, V1
WINTHER, K1
Cleren, C1
Starkov, AA1
Calingasan, NY1
Lorenzo, BJ1
Chen, J1
Beal, MF1

Other Studies

6 other studies available for promethazine and Parkinsonian Disorders

ArticleYear
Treatment of parkinsonism; preliminary report on use of promethazine in 12 cases.
    The American journal of psychiatry, 1957, Volume: 114, Issue:6

    Topics: Humans; Parkinson Disease; Parkinsonian Disorders; Promethazine

1957
[CONTRIBUTION TO THE THERAPY AND REHABILITATION OF PARKINSON'S SYNDROME].
    Wiener Zeitschrift fur Nervenheilkunde und deren Grenzgebiete, 1963, Volume: 21

    Topics: Histamine H1 Antagonists; Neurosurgery; Orphenadrine; Parasympatholytics; Parkinson Disease; Parkins

1963
INTERCHANGEABLITY OF ANTIPARKINSONIAN MEDICATION.
    The American journal of psychiatry, 1964, Volume: 120

    Topics: Antiparkinson Agents; Biomedical Research; Extrapyramidal Tracts; Geriatrics; Humans; Parasympatholy

1964
[Antagonism of dibenzothiazine derivatives (diparcol, parsidol, phenergan) towards the central effects of nicotine; correspondence with clinical experimentation in Parkinson's disease].
    Comptes rendus des seances de la Societe de biologie et de ses filiales, 1950, Volume: 144, Issue:7-8

    Topics: Empirical Research; Histamine Antagonists; Nicotine; Parkinson Disease; Parkinsonian Disorders; Phen

1950
[Treatment of paralysis agitans with some new preparations: parpanit, diparcol, and phenergan].
    Ugeskrift for laeger, 1950, May-25, Volume: 112, Issue:21

    Topics: Cyclopentanes; Histamine; Parkinson Disease; Parkinsonian Disorders; Phenothiazines; Promethazine

1950
Promethazine protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.
    Neurobiology of disease, 2005, Volume: 20, Issue:3

    Topics: 1-Methyl-4-phenylpyridinium; Animals; Calcium; Calcium Signaling; Disease Models, Animal; Dopamine;

2005
chemdatabank.com